The CEO called the finding too important not to pursue, but the work and funding needed to develop an Alzheimers drug is well outside of Ultragenyxs rare disease focus. So Ultragenyx is forming a new company called Amlogenyx to capitalize on the highrisk high return discovery. The spinout will be cash neutral for Ultragenyx the CEO said